Impact Biomedical Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The company is a development-stage healthcare and wellness technology business and a subsidiary of DSS, Inc. It seeks to develop and commercialize intellectual property mainly through licensing and partnerships, with potential direct product sales. Its portfolio includes Linebacker and Equivir, licensed to ProPhase Labs for development; Laetose; and Functional Fragrance Formulation (3F). The company reports one operating segment.
Financial performance and position
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $0 | $50,000 |
| Operating expenses | $4.028 million | $3.454 million |
| Operating loss | $4.028 million | $3.404 million |
| Net loss | $4.407 million | $7.255 million |
| Net loss attributable to common stockholders | $4.336 million | $7.051 million |
| Net cash used in operating activities | $2.851 million | $2.242 million |
| Net cash used in investing activities | $15,000 | $349,000 |
| Cash provided by financing activities | $2.865 million | $2.547 million |
- Revenue and margins: 2023 revenue was nil, versus $50,000 of ProPhase milestone revenue in 2022. With no 2023 revenue, a meaningful operating margin is not available.
- Expense changes: Professional services rose 75% to $1.262 million, mainly for consulting, legal, patenting and business-plan work. Research and development fell 6% to $1.147 million; SG&A compensation fell 3% to $315,000. Total costs and expenses increased 17%.
- Loss comparison: Net loss narrowed from 2022, primarily because 2022 included a $4.1 million impairment of the Vivacitas investment. Operating loss increased in 2023 despite the lower net loss.
- Liquidity: Cash was approximately $1,000 at year-end. Current assets were $332,000 and current liabilities were $13.136 million, an implied working-capital deficit of about $12.804 million.
- Debt: The related-party note payable to DSS was $12.074 million at December 31, 2023, compared with $9.991 million a year earlier. The company relies on DSS borrowings to fund operations.
- Assets and equity: Total assets were $44.633 million, including $25.093 million of goodwill and $18.921 million of net intangible assets. Total liabilities were $16.371 million and total stockholders’ equity, including noncontrolling interests, was $28.262 million.
Material changes and developments
- DSS distributed approximately 8.821 million Impact BioMedical shares to its shareholders in August 2023.
- The company effected a 1-for-55 reverse stock split in October 2023 and converted 60,496,041 common shares held by DSS BioHealth Security into Series A Convertible Preferred Stock. The filing reports 10 million common shares outstanding as of February 14, 2024; some financial-statement and transaction descriptions show different share counts. See investor verification items below.
- 2023 operating expenses included $1.120 million of amortization, primarily for acquired developed technology and patents. No goodwill or intangible-asset impairment was reported for 2023.
- The company reported no dividends and no share repurchases in 2023. Its common stock was not listed on an exchange at the time described in the filing; it stated an intention to seek NYSE American listing.
Outlook, risks and unusual items
- Going concern: The auditor’s unmodified opinion includes a substantial-doubt paragraph. The company says recurring losses and negative operating and investing cash flows raise substantial doubt about its ability to continue as a going concern. DSS intends to fund operations for at least a year from the financial statements’ issuance date, but that support is not assured by an independent source.
- DSS financing: A January 2024 amendment extended the related-party note maturity to September 30, 2030, set the rate at WSJ prime plus 0.50% (initially 9%), and secured the note with a first lien on company assets, including licenses and patents. The amendment provides for payment on demand or scheduled repayments if no demand is made. The filing reports a funded principal balance of approximately $12.859 million under the amended arrangement.
- Business outlook: Management cited ongoing ProPhase studies of Linebacker, with preliminary results expected in Q1 2024, and Equivir studies with results expected in Q1 or Q2 2024. An over-the-counter offering was projected for the second half of 2024 subject to successful results. These are expectations, not assured outcomes. Management also expects potential licensing revenue from Laetose and 3F, but reports no such revenue in 2023.
- Funding and commercialization risks: The business has no significant operating revenue and depends on financing, partner performance, successful research and development, regulatory approvals, enforceable intellectual property and future licensing or product sales. Clinical and regulatory failure, competition, patent challenges and delays could impair prospects and asset values.
- Contingencies and related parties: The company disclosed a 3F revenue-sharing arrangement with Chemia and a GRDG agreement granting a share of certain licensing proceeds. It also reported $200,000 recorded in connection with potential Equivir development-cost reimbursement obligations. In 2023, approximately $94,000 of healthcare products sold to related party SHRG was deemed uncollectible and written off.
- Controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end. Identified material weaknesses included insufficient qualified accounting personnel and segregation of duties, and lack of systematic documentation of monthly close and reconciliations. Remediation steps are underway but were not fully documented and tested for effectiveness.
- Audit: The financial statements received an unmodified GAAP audit opinion, accompanied by the going-concern emphasis. The auditor was not engaged to opine on internal control effectiveness.
Most important facts for investors to verify
- Reconcile the filing’s differing common-share counts and corporate-action descriptions, including the post-split shares, preferred conversion, and current capitalization. Confirm the preferred stock’s conversion, voting and economic terms and resulting ownership.
- Review the DSS note amendment, including its demand feature, interest rate, repayment schedule, first lien and the extent and duration of DSS’s stated funding commitment.
- Track actual ProPhase study results, development responsibilities, regulatory requirements and the timing and conditions for any product launch or milestone payments.
- Confirm the status, ownership, enforceability and remaining duration of key patents, and the economics and obligations under ProPhase, Chemia and GRDG agreements.
- Monitor cash needs, financing or IPO/listing progress, and whether the company can address the going-concern uncertainty without relying solely on related-party support.
- Check whether management documents and tests its control-remediation measures and reports that the material weaknesses have been resolved.